SG11201506398SA - Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection - Google Patents

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Info

Publication number
SG11201506398SA
SG11201506398SA SG11201506398SA SG11201506398SA SG11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA
Authority
SG
Singapore
Prior art keywords
eimeria
compositions
methods
immune responses
limiting
Prior art date
Application number
SG11201506398SA
Inventor
John R Barta
Luc Berghman
Lisa Bielke
Billy Hargis
Srichaitanya Shivaramaiah
Olivia B Faulkner
Original Assignee
Univ Arkansas
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Texas A & M Univ Sys filed Critical Univ Arkansas
Publication of SG11201506398SA publication Critical patent/SG11201506398SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201506398SA 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection SG11201506398SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764681P 2013-02-14 2013-02-14
PCT/US2014/016359 WO2014127185A1 (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Publications (1)

Publication Number Publication Date
SG11201506398SA true SG11201506398SA (en) 2015-09-29

Family

ID=51354559

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201506398SA SG11201506398SA (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
SG10202109925T SG10202109925TA (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202109925T SG10202109925TA (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Country Status (24)

Country Link
US (6) US9603915B2 (en)
EP (2) EP2956165B1 (en)
JP (2) JP6532407B2 (en)
KR (1) KR102228324B1 (en)
CN (2) CN111956796A (en)
AR (1) AR094791A1 (en)
AU (1) AU2014216246B2 (en)
BR (1) BR112015019283B1 (en)
CA (1) CA2900644C (en)
CL (1) CL2015002273A1 (en)
DK (1) DK2956165T3 (en)
EA (1) EA030929B1 (en)
ES (1) ES2758759T3 (en)
HK (1) HK1218880A1 (en)
HU (1) HUE047484T2 (en)
MX (1) MX2015010555A (en)
MY (1) MY173328A (en)
NZ (1) NZ711019A (en)
PH (1) PH12015501784B1 (en)
PL (1) PL2956165T3 (en)
PT (1) PT2956165T (en)
SG (2) SG11201506398SA (en)
WO (1) WO2014127185A1 (en)
ZA (1) ZA201505638B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704422C (en) * 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EP2968423A4 (en) 2013-03-15 2016-11-09 Univ Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
CN104940924B (en) * 2015-05-29 2018-01-16 中国农业大学 A kind of coccidia adjuvant and its application
TW202224701A (en) * 2016-05-03 2022-07-01 阿肯色州大學董事會 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
CN106047914A (en) * 2016-05-10 2016-10-26 吉林大学 A recombinant bacillus calmette-guerin vaccine used for preventing toxoplasmosis in pigs and a preparing method thereof
WO2018226887A1 (en) * 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229221T2 (en) 1991-03-05 1999-09-23 Wellcome Found EXPRESSION OF RECOMBINANT PROTEINS IN ATTENUATED BACTERIA
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
EP0667901B2 (en) 1991-10-25 2008-10-15 Immunex Corporation Novel cytokine
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
EP0659086B1 (en) 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
US5817516A (en) 1994-04-28 1998-10-06 Boehringer Ingelheim Pharmaceuticals, Inc. Methods for proliferating and differentiating B cells with high density membrane CD40 ligand
WO1996026735A1 (en) 1995-03-01 1996-09-06 Immunex Corporation Method for stimulating an immune response
KR100453314B1 (en) 1995-06-07 2004-12-17 임뮤넥스 코포레이션 CD40L Mutein
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
IL136731A0 (en) 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (en) 1998-05-19 2000-03-16 Vander Way Limited USE OF HMG-I PROTEIN FOR THE PREPARATION OF MEDICATIONS WITH CYTOTOXIC ACTIVITY
DK1108034T3 (en) 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Attenuated salmonella SPI2 mutants as antigen carriers
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
IL144952A0 (en) 1999-04-16 2002-06-30 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
EP1246643A4 (en) 1999-10-14 2005-05-11 Jeffery A Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
EP1112747B1 (en) 1999-12-28 2004-06-16 Akzo Nobel N.V. Salmonella vaccine not inducing antibodies against flagellin or flagella
EP1255560B1 (en) 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40 ligand adjuvant for respiratory syncytial virus vaccine
DE60112413T2 (en) 2000-03-17 2006-06-01 Pharmacia & Upjohn Co. Llc, Kalamazoo SSA INACTIVATED SALMONELLA VACCINES
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
US20030165538A1 (en) 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7811816B2 (en) 2001-05-15 2010-10-12 Ortho-Mcneil Pharmaeutical, Inc. Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN100447154C (en) 2001-05-15 2008-12-31 费因斯坦医学研究学院 Use of HMG fragments as anti-inflammatory agents
BR0210850A (en) 2001-07-06 2004-12-07 Biolog Lab Teva Ltd nucleic acids encoding a recombinant 250 kda antigen of maximum eimeria sporozoites / merozoites and their uses
ZA200400479B (en) 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
ITMI20011986A1 (en) 2001-09-25 2003-03-25 San Raffaele Centro Fond METHOD AND COMPOSITION FOR THE ACTIVATION OF CELLS PRESENTING THE ANTIGEN
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
AU2002358771B2 (en) 2001-12-19 2009-04-23 Alcedo Biotech Gmbh Use of HMGB proteins and nucleic acids that code therefor
US7238499B2 (en) 2001-12-21 2007-07-03 Immunex Corporation Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
JP4304077B2 (en) 2002-02-13 2009-07-29 イミュノロジー ラボラトリーズ インコーポレイテッド Compositions and methods for the treatment of microbial infections
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
ATE556596T1 (en) 2002-04-15 2012-05-15 Univ St Louis REGULATED ATTENUATION OF LIVE VACCINES TO IMPROVE CROSS-IMMMUNITY PROTECTIVE FUNCTION
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
WO2004046338A2 (en) 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Use of hmgb polypeptides for increasing immune responses
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2006083301A2 (en) 2004-06-17 2006-08-10 Medimmune, Inc. Immunogenic compositions comprising hmgb1 polypeptides
US20080075728A1 (en) 2004-07-20 2008-03-27 Walter Newman Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
US20090011426A1 (en) * 2004-08-19 2009-01-08 Mackintosh James A Methods of Diagnosis and Treatment of M.Tuberculosis Infection and Reagents Therefor
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
RS51402B (en) 2005-10-07 2011-02-28 Proyecto De Biomedicina Cima, S.L. Immunostimulatory combinaton for the prophylactics and treatment of hepatitis c
JP2009514536A (en) 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター CD40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CN101024076B (en) 2007-03-29 2010-08-18 中国农业大学 Novel use of coccidium
BRPI0818736A2 (en) 2007-10-30 2017-06-13 Univ Arkansas compositions and methods for enhancing immunoresponders to flagellated bacteria
CA2704422C (en) * 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
CN101234196A (en) 2007-11-30 2008-08-06 吉林大学 Coccidiosis recombination bacillus calmette-guerin vaccine and preparation
WO2010029164A1 (en) 2008-09-11 2010-03-18 Institut Pasteur Monitoring and inhibiting human immunodeficiency virus infection by modulating hmgb1 dependent triggering of hiv-1 replication and persistence
EP2355844A2 (en) 2008-11-13 2011-08-17 Intervet International BV Eimeria vaccine for turkeys
US20100150958A1 (en) 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
JP2011072284A (en) * 2009-10-01 2011-04-14 Mitsubishi Chemicals Corp Method for producing antibody and immunogenic composition usable therefor
AU2011207331C1 (en) 2010-01-21 2016-05-12 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
JP6284537B2 (en) 2012-10-29 2018-02-28 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Novel mucosal adjuvant and delivery system
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EP2968423A4 (en) 2013-03-15 2016-11-09 Univ Arkansas Compositions and methods of enhancing immune responses to enteric pathogens

Also Published As

Publication number Publication date
PL2956165T3 (en) 2020-04-30
US10328137B2 (en) 2019-06-25
CA2900644A1 (en) 2014-08-21
EP2956165A4 (en) 2016-09-21
KR102228324B1 (en) 2021-03-15
US11364290B2 (en) 2022-06-21
JP6874031B2 (en) 2021-05-19
JP2019073554A (en) 2019-05-16
JP2016513956A (en) 2016-05-19
EA201591488A1 (en) 2016-01-29
AU2014216246A2 (en) 2015-10-01
EP3610887B8 (en) 2024-01-24
US11904005B2 (en) 2024-02-20
EP2956165A1 (en) 2015-12-23
ES2758759T3 (en) 2020-05-06
SG10202109925TA (en) 2021-10-28
EP3610887A1 (en) 2020-02-19
PH12015501784A1 (en) 2015-12-07
AR094791A1 (en) 2015-08-26
MX2015010555A (en) 2015-09-28
WO2014127185A1 (en) 2014-08-21
BR112015019283A2 (en) 2017-07-18
AU2014216246A8 (en) 2015-11-19
KR20150119110A (en) 2015-10-23
US20190298815A1 (en) 2019-10-03
US10792351B2 (en) 2020-10-06
PH12015501784B1 (en) 2015-12-07
NZ711019A (en) 2019-07-26
HK1218880A1 (en) 2017-03-17
DK2956165T3 (en) 2019-12-02
MY173328A (en) 2020-01-16
CN111956796A (en) 2020-11-20
CA2900644C (en) 2023-03-14
CN105142665A (en) 2015-12-09
US20170182136A1 (en) 2017-06-29
CL2015002273A1 (en) 2015-12-04
US20220288175A1 (en) 2022-09-15
JP6532407B2 (en) 2019-06-19
AU2014216246B2 (en) 2018-12-20
ZA201505638B (en) 2023-05-31
US20210008184A1 (en) 2021-01-14
AU2014216246A1 (en) 2015-09-10
US20180169198A1 (en) 2018-06-21
HUE047484T2 (en) 2020-04-28
US9884099B2 (en) 2018-02-06
US9603915B2 (en) 2017-03-28
EP3610887C0 (en) 2023-11-15
EA030929B1 (en) 2018-10-31
PT2956165T (en) 2019-11-29
EP3610887B1 (en) 2023-11-15
BR112015019283B1 (en) 2023-12-19
EP2956165B1 (en) 2019-09-11
US20160000895A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
HK1218880A1 (en) Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
HK1212729A1 (en) Riboregulator compositions and mehtods of use
HK1207001A1 (en) Immunostimulatory compositions and methods of use thereof
EP2964235A4 (en) Antimicrobial-antibiofilm compositions and methods of use thereof
HK1219045A1 (en) Compositions and methods of enhancing immune responses to enteric pathogens
GB201320723D0 (en) Composition and methods of treatment
HK1221416A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
HK1210187A1 (en) Compositions and methods related to prevention and treatment of rabies infection
EP2968244A4 (en) Compositions and methods for utilization of algal compounds
HK1221641A1 (en) Vaccine composition and method of use
EP2897639A4 (en) Improved vaccine compositions and methods of use
HK1209031A1 (en) Polysaccharide compositions and methods of use
HK1254514A1 (en) Methods and compositions for enhancing immune response to vaccination
HK1217715A1 (en) Compositions and methods for treatment of stroke
IL244537A0 (en) Novel delivery compositions and methods of using same
HK1203979A1 (en) Compositions and methods of modulating an immune response
EP2931040A4 (en) Methods and compositions of treating hiv infection
IL243331B (en) Methods and compositions of granule formulations
EP2841164A4 (en) Dermal-appropriate compositions and methods of use
GB201314498D0 (en) Improvements to Receivers and Method of Use Thereof